MicroRNA‐122 can be measured in capillary blood which facilitates point‐of‐care testing for drug‐induced liver injury

Abstract

This work supports the potential use of miR-122 as biomarker of human DILI when measured in a capillary blood drop. With development across DILI aetiologies, this could be used by novel point-of-care technologies to produce a minimally invasive, near-patient, diagnostic test.